EGFR and non-small cell lung carcinoma: However, the discovery of oncogenic driver mutations, such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) rearrangement, has led to the development of molecular targeted therapy for NSCLC, which in turn has drastically improved patient survival.3, 4